267 related articles for article (PubMed ID: 26147305)
1. Understanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule Inhibitors.
Peron M; Lovisa F; Poli E; Basso G; Bonvini P
PLoS One; 2015; 10(7):e0132330. PubMed ID: 26147305
[TBL] [Abstract][Full Text] [Related]
2. Rhabdomyosarcoma cells are susceptible to cell death by LDK378 alone or in combination with sorafenib independently of anaplastic lymphoma kinase status.
Dolgikh N; Fulda S
Anticancer Drugs; 2017 Nov; 28(10):1118-1125. PubMed ID: 29045271
[TBL] [Abstract][Full Text] [Related]
3. Crizotinib-induced antitumour activity in human alveolar rhabdomyosarcoma cells is not solely dependent on ALK and MET inhibition.
Megiorni F; McDowell HP; Camero S; Mannarino O; Ceccarelli S; Paiano M; Losty PD; Pizer B; Shukla R; Pizzuti A; Clerico A; Dominici C
J Exp Clin Cancer Res; 2015 Oct; 34():112. PubMed ID: 26445453
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice.
van Gaal JC; Roeffen MH; Flucke UE; van der Laak JA; van der Heijden G; de Bont ES; Suurmeijer AJ; Versleijen-Jonkers YM; van der Graaf WT
Eur J Cancer; 2013 Nov; 49(16):3462-70. PubMed ID: 23867124
[TBL] [Abstract][Full Text] [Related]
5. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
Guenther MK; Graab U; Fulda S
Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
[TBL] [Abstract][Full Text] [Related]
6. Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib.
van Erp AEM; Hillebrandt-Roeffen MHS; van Houdt L; Fleuren EDG; van der Graaf WTA; Versleijen-Jonkers YMH
Target Oncol; 2017 Dec; 12(6):815-826. PubMed ID: 29067644
[TBL] [Abstract][Full Text] [Related]
7. Targeting ALK in pediatric RMS does not induce antitumor activity in vivo.
Wierdl M; Tsurkan L; Chi L; Hatfield MJ; Tollemar V; Bradley C; Chen X; Qu C; Potter PM
Cancer Chemother Pharmacol; 2018 Aug; 82(2):251-263. PubMed ID: 29855693
[TBL] [Abstract][Full Text] [Related]
8. Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma.
Graab U; Hahn H; Fulda S
Oncotarget; 2015 Apr; 6(11):8722-35. PubMed ID: 25749378
[TBL] [Abstract][Full Text] [Related]
9. Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma.
McKinnon T; Venier R; Yohe M; Sindiri S; Gryder BE; Shern JF; Kabaroff L; Dickson B; Schleicher K; Chouinard-Pelletier G; Menezes S; Gupta A; Zhang X; Guha R; Ferrer M; Thomas CJ; Wei Y; Davani D; Guidos CJ; Khan J; Gladdy RA
Oncogene; 2018 May; 37(20):2630-2644. PubMed ID: 29487419
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274.
Hou J; Dong J; Sun L; Geng L; Wang J; Zheng J; Li Y; Bridge J; Hinrichs SH; Ding SJ
J Transl Med; 2011 May; 9():64. PubMed ID: 21575221
[TBL] [Abstract][Full Text] [Related]
11. Anaplastic lymphoma kinase aberrations correlate with metastatic features in pediatric rhabdomyosarcoma.
Gasparini P; Casanova M; Villa R; Collini P; Alaggio R; Zin A; Bonvini P; Antonescu CR; Boldrini R; Caserini R; Moro M; Centonze G; Meazza C; Massimino M; Bergamaschi L; Luksch R; Chiaravalli S; Bisogno G; Zaffaroni N; Daidone MG; Sozzi G; Ferrari A
Oncotarget; 2016 Sep; 7(37):58903-58914. PubMed ID: 27385213
[TBL] [Abstract][Full Text] [Related]
12. Receptor tyrosine kinases and their activation in melanoma.
Easty DJ; Gray SG; O'Byrne KJ; O'Donnell D; Bennett DC
Pigment Cell Melanoma Res; 2011 Jun; 24(3):446-61. PubMed ID: 21320293
[TBL] [Abstract][Full Text] [Related]
13. Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications.
van Gaal JC; Flucke UE; Roeffen MH; de Bont ES; Sleijfer S; Mavinkurve-Groothuis AM; Suurmeijer AJ; van der Graaf WT; Versleijen-Jonkers YM
J Clin Oncol; 2012 Jan; 30(3):308-15. PubMed ID: 22184391
[TBL] [Abstract][Full Text] [Related]
14. PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound.
Cen L; Hsieh FC; Lin HJ; Chen CS; Qualman SJ; Lin J
Br J Cancer; 2007 Sep; 97(6):785-91. PubMed ID: 17848913
[TBL] [Abstract][Full Text] [Related]
15. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
Phuchareon J; McCormick F; Eisele DW; Tetsu O
Proc Natl Acad Sci U S A; 2015 Jul; 112(29):E3855-63. PubMed ID: 26150526
[TBL] [Abstract][Full Text] [Related]
16. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
[TBL] [Abstract][Full Text] [Related]
17. Effect of tumor necrosis factor-alpha on the phosphorylation of tyrosine kinase receptors is associated with dynamic alterations in specific protein-tyrosine phosphatases.
Ahmad F; Goldstein BJ
J Cell Biochem; 1997 Jan; 64(1):117-27. PubMed ID: 9015760
[TBL] [Abstract][Full Text] [Related]
18. New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
Di Paolo D; Yang D; Pastorino F; Emionite L; Cilli M; Daga A; Destafanis E; Di Fiore A; Piaggio F; Brignole C; Xu X; Liang C; Gibbons J; Ponzoni M; Perri P
Oncotarget; 2015 Oct; 6(30):28774-89. PubMed ID: 26299615
[TBL] [Abstract][Full Text] [Related]
19. Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.
Wang Y; Wang L; Guan S; Cao W; Wang H; Chen Z; Zhao Y; Yu Y; Zhang H; Pang JC; Huang SL; Akiyama Y; Yang Y; Sun W; Xu X; Shi Y; Zhang H; Kim ES; Muscal JA; Lu F; Yang J
Sci Rep; 2016 Jan; 6():19423. PubMed ID: 26786851
[TBL] [Abstract][Full Text] [Related]
20. Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study.
Lee JS; Lim SM; Rha SY; Roh JK; Cho YJ; Shin KH; Yang WI; Kim SH; Kim HS
J Clin Pathol; 2014 Jan; 67(1):33-9. PubMed ID: 23922356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
